Stockscreener 앱 받기
23.67
0.13%
-0.03
시간 외 거래:
23.67
전일 마감가:
$23.70
열려 있는:
$24.06
하루 거래량:
303.08K
Relative Volume:
1.19
시가총액:
$700.56M
수익:
$4.12M
순이익/손실:
$-56.68M
주가수익비율:
-4.2703
EPS:
-5.5429
순현금흐름:
$-51.44M
1주 성능:
-3.35%
1개월 성능:
+9.28%
6개월 성능:
-17.03%
1년 성능:
-1.25%
1일 변동 폭
$23.37
$24.83
1주일 범위
$22.77
$25.27
52주 변동 폭
$18.34
$33.77
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
명칭
Dianthus Therapeutics Inc
전화
857-201-2700
주소
300 TECHNOLOGY SQUARE, CAMBRIDGE
DNTH을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DNTH
Dianthus Therapeutics Inc
|
23.67 | 700.56M | 4.12M | -56.68M | -51.44M | -5.5429 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-20 | 개시 | TD Cowen | Buy |
| 2024-10-03 | 개시 | Oppenheimer | Outperform |
| 2024-07-26 | 개시 | Robert W. Baird | Outperform |
| 2024-06-27 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-05-16 | 개시 | H.C. Wainwright | Buy |
| 2024-02-15 | 개시 | Stifel | Buy |
| 2023-12-26 | 개시 | Jefferies | Buy |
| 2023-11-22 | 개시 | Wedbush | Outperform |
| 2023-10-30 | 개시 | Guggenheim | Buy |
| 2023-09-28 | 개시 | Raymond James | Outperform |
| 2022-08-25 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-01-06 | 업그레이드 | Goldman | Neutral → Buy |
| 2021-08-20 | 재개 | Goldman | Neutral |
| 2021-08-03 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-07-22 | 재확인 | B. Riley Securities | Buy |
| 2021-06-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-06-15 | 개시 | BTIG Research | Buy |
| 2021-05-18 | 개시 | B. Riley Securities | Buy |
| 2021-01-07 | 개시 | Mizuho | Buy |
| 2020-06-08 | 업그레이드 | Goldman | Neutral → Buy |
| 2019-03-25 | 다운그레이드 | Goldman | Buy → Neutral |
| 2019-03-15 | 개시 | Raymond James | Outperform |
모두보기
Dianthus Therapeutics Inc 주식(DNTH)의 최신 뉴스
Brokerages Set Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Target Price at $46.83 - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Rating of “Buy” by Analysts - Defense World
Dianthus Therapeutics (NASDAQ:DNTH) Trading 8% HigherShould You Buy? - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Short Interest Update - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Purchased by SG Americas Securities LLC - Defense World
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Short Interest Up 6.0% in January - MarketBeat
Octagon Capital Advisors LP Increases Stake in Dianthus Therapeu - GuruFocus.com
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Sees Significant Increase in Short Interest - Defense World
Dianthus Therapeutics to Webcast Presentations at Two Investor Conferences - The Manila Times
Exclusive: Dianthus Therapeutics Reveals Next-Gen Autoimmune Pipeline at Elite Investor Summits - StockTitan
Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 4.6%Here's Why - MarketBeat
Equities Analysts Issue Forecasts for DNTH FY2025 Earnings - Defense World
Cantor Fitzgerald Comments on DNTH FY2025 Earnings - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Average Rating of “Buy” by Analysts - Defense World
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Sees Significant Growth in Short Interest - MarketBeat
A Dive Into Dianthus Therapeutics: Little To Move The Stock (NASDAQ:DNTH) - Seeking Alpha
Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 5.5%Here's Why - MarketBeat
Barclays PLC Purchases 33,185 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Barclays PLC Acquires 33,185 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Dianthus Therapeutics to Webcast Presentation at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Dianthus Therapeutics CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 6.8%Should You Sell? - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Up 7.8%Here's What Happened - MarketBeat
Jane Street Group LLC Takes $556,000 Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Stake Trimmed by Geode Capital Management LLC - Defense World
Barclays PLC Boosts Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Stock Position Raised by Barclays PLC - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Average Rating of “Buy” by Brokerages - Defense World
Dianthus Therapeutics (NASDAQ:DNTH) Shares Down 2.5%Here's Why - MarketBeat
State Street Corp Increases Stock Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
State Street Corp Increases Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
TD Cowen Initiates Coverage on Dianthus Therapeutics (NASDAQ:DNTH) - Defense World
Forecasting The Future: 5 Analyst Projections For Dianthus Therapeutics - Benzinga
Dianthus Therapeutics (NASDAQ:DNTH) Now Covered by TD Cowen - MarketBeat
Wellington Management Group LLP Invests $1.47 Million in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Upgraded at Raymond James - Defense World
Raymond James Upgrades Dianthus Therapeutics (NASDAQ:DNTH) to Moderate Buy - MarketBeat
Charles Schwab Investment Management Inc. Increases Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Charles Schwab Investment Management Inc. Boosts Stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
MetLife Investment Management LLC Purchases 7,854 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Point72 Asset Management L.P. Buys 263,500 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Dianthus Therapeutics Inc (DNTH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.27%
3.05%
자본화:
|
볼륨(24시간):